 LAWRENCEVILLE, N.J., March 02, 2021 GLOBE NEWSWIRE -- Celsion Corporation NASDAQ: CLSN, a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster on the Companys Phase III OVATION 2 Study with GEN-1 in advanced ovarian cancer has been accepted for presentation at the Virtual Annual Meeting on Womens Cancer, sponsored by the Society of Gynecologic Oncology. 